Equities
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)15.13
  • Today's Change0.14 / 0.93%
  • Shares traded1.74m
  • 1 Year change+105.29%
  • Beta1.1574
Data delayed at least 15 minutes, as of Feb 13 2026 08:08 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

China Medical System Holdings Ltd is an investment holding company principally engaged in the production of medicines, as well as marketing, promotion and sales of drugs. The Company's products include Plendil, Ursofalk, Augentropfen Stulln Mono Eye Drops, Hirudoid, Atopic Piel Series and Vmonalisa, among others. Its major marketed products cover the cardio-cerebrovascular, gastroenterology, ophthalmology, dermatology and medical aesthetic fields. The Company distributes its products within domestic market and to overseas markets.

  • Revenue in HKD (TTM)8.89bn
  • Net income in HKD1.87bn
  • Incorporated2006
  • Employees6.10k
  • Location
    China Medical System Holdings LtdUnit 2106, 21/F, Island Place Tower, 510, North Point Hong KongHKG
  • Phone+86 75 582416868
  • Fax+86 75 582416622
  • Websitehttps://web.cms.net.cn/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Ab&B Bio Tech Co Ltd JS366.15m-253.82m20.18bn583.00--530.23--55.12-0.6451-0.64510.93060.0968----------------67.29---69.32--0.3162-9.490.9646--397.65--39.09------
HUTCHMED (China) Ltd4.71bn3.65bn20.22bn1.78k5.542.105.394.304.184.185.3911.020.39667.093.862,599,556.0030.79-9.5540.72-13.7744.1539.8477.64-20.324.51--0.07---24.8025.20-62.56--15.93--
Sunshine Lake Pharma Co Ltd3.82bn-447.80m24.19bn6.53k--54.7420,257.626.34-0.7765-0.77656.620.7672------582,679.50--------73.62---12.86--0.7739-0.75910.5111---37.06---212.17------
The United Laboratories Intl. Hldgs Ltd.15.95bn3.46bn24.90bn17.40k6.621.305.981.561.911.918.789.690.53972.895.97938,145.0011.719.3717.4614.5447.2444.3321.7015.061.60--0.247226.010.138710.39-1.5432.8937.2545.96
Shanghai Henlius Biotech Inc6.56bn932.24m24.90bn3.54k41.9510.1517.653.801.721.7212.067.090.53861.735.861,865,468.007.66-3.2113.85-5.7675.7772.5014.22-7.870.504610.470.5185--6.11128.9850.26--10.83--
PegBio Co Ltd-100.00bn-100.00bn26.11bn58.00--89.25----------0.7479------------------------3.07--0.2439-------1.49------
Grand Pharmaceutical Group Ltd11.70bn2.08bn26.83bn12.44k12.721.5410.352.290.59430.59433.354.900.45573.663.88976,472.807.9910.4010.8114.2457.6461.0417.5322.800.9872--0.210729.1210.5912.0631.3016.490.739822.05
China Resources Pharmaceutical Group Ltd295.11bn3.19bn29.34bn86.00k9.190.51922.250.09940.50830.508346.978.990.94345.572.414,059,329.002.863.1410.2811.7815.8115.593.033.021.1211.260.424822.385.307.41-13.062.9512.427.30
Duality Biotherapeutics Inc2.45bn-3.20bn29.48bn191.00--8.74--12.01-36.93-36.9328.6737.42------14,438,690.00--------37.13---130.43------0.0228--8.66---193.82------
Simcere Pharmaceutical Group Ltd8.04bn995.43m31.88bn6.82k30.353.7122.873.970.40470.40473.263.310.58452.202.811,220,719.007.248.749.9312.4281.0078.5312.3915.601.574.720.145344.120.41485.672.57-6.098.48--
Xuanzhu Biopharmaceutical Co Ltd36.14m-629.22m33.93bn197.00--35.47--938.68-1.21-1.210.06981.85----------------41.02---1,740.97--1.10--0.0013--103,672.40---85.13------
China Medical System Holdings Ltd8.89bn1.87bn36.57bn6.10k19.411.9016.954.110.77210.77213.687.890.42393.146.121,447,511.008.8516.359.8818.7071.4775.0320.8832.205.28--0.041740.16-6.794.22-32.54-3.756.01-2.60
Data as of Feb 13 2026. Currency figures normalised to China Medical System Holdings Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

15.64%Per cent of shares held by top holders
HolderShares% Held
Lazard Asset Management LLCas of 28 Jul 2025121.07m4.96%
Norges Bank Investment Managementas of 30 Jun 202555.66m2.28%
The Vanguard Group, Inc.as of 07 Jan 202647.48m1.95%
Foresight Fund Management Co., Ltd.as of 30 Jun 202529.56m1.21%
Dimensional Fund Advisors LPas of 08 Jan 202628.40m1.16%
GF Fund Management Co., Ltd.as of 30 Jun 202525.07m1.03%
Fidelity Management & Research Co. LLCas of 30 Nov 202524.96m1.02%
Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt)as of 30 Jun 202517.12m0.70%
BlackRock Fund Advisorsas of 09 Jan 202616.72m0.69%
China Universal Asset Management Co., Ltd.as of 30 Jun 202515.55m0.64%
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.